Press Releases


Press Releases

Webcast
Xenon Pharmaceuticals at the 31st Annual Piper Jaffray Healthcare Conference
Wednesday, December 4, 2019 3:00 pm EST
November 15, 2019
BURNABY, British Columbia , Nov. 15, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone , Xenon's Chief Executive Officer, will participate in the following investor conferences and present a company ...
January 28, 2019
FDA Grants Rare Pediatric Disease Designation to XEN007 for Alternating Hemiplegia of Childhood (AHC); Xenon Eligible to Apply for Priority Review Voucher IND for XEN1101 Accepted; Site Selection and Patient Enrollment Underway in Canada and the United States for XEN1101 Phase 2b Clinical Trial ...
January 6, 2019
Innovative Product Pipeline Includes Multiple Neurology-Focused Products Anticipated to be in Phase 2 or Later Stage Development in 2019 BURNABY, British Columbia , Jan. 06, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today provided ...